Introduction
Before this report, I have written two other Seeking Alpha reports about Acasti Pharma (ACST) in 2019, espousing ACST’s profound market opportunity and its leading drug CaPre’s competitive advantages; my first report in June was published when the stock was only $1.01/share. Yesterday, ACST closed at $2.08/share, demonstrating a 106% return in 5 months, since my first report. While the stock has made some progress, it has a long way to go, and from the second report (please see article below for valuation section), the price target of $11.06/share may prove conservative,